查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1938816

慢性特发性便秘治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类别、给药途径、通路、地区及竞争格局划分，2021-2031年）

Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球慢性特发性便秘治疗市场预计将从 2025 年的 115.3 亿美元成长到 2031 年的 164.6 亿美元，复合年增长率为 6.11%。

本板块涵盖专门针对无法明确生理或系统性病因的持续性便秘病例而研发的药物和处方治疗方案。推动该板块成长的主要因素包括功能性胃肠疾病盛行率的上升、全球人口老化导致结肠动力减弱，以及医疗保健领域对慢性病管理投入的增加。此外，久坐生活方式的兴起和饮食习惯的改变也扩大了就医人群。国际胃肠疾病基金会指出，到2024年，全球约有六分之一到七分之一的人口将受到便秘的困扰，凸显了有效治疗方案的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 115.3亿美元
市场规模：2031年 164.6亿美元
复合年增长率：2026-2031年 6.11%
成长最快的细分市场 肠外
最大的市场 北美洲

儘管有这些正面因素，市场仍面临一项重大挑战：消费者普遍依赖非处方药和膳食补充剂。许多出现症状的患者选择使用价格低廉且易于获得的替代品进行自我治疗，而不是寻求专业医疗建议，这种趋势减缓了向更先进的处方治疗方案的过渡。这一趋势显着限制了专门用于治疗慢性特发性便秘的药物的目标患者群体，并阻碍了该细分市场的收入成长。

市场驱动因素

慢性特发性便秘在全球日益普遍，这主要受久坐少动的生活方式和饮食习惯改变的影响，也是推动市场扩张的主要因素。加速的都市化和体力活动减少导致功能性肠道疾病的盛行率上升，使得寻求医疗服务的患者人数不断增加。这一趋势导致患者从非处方药转向处方药，从而对成熟治疗方法产生了稳定的需求。近期产业指标也反映了这一趋势，Ironwood Pharmaceuticals于2025年12月发布的2025年第三季财务报告显示，LINZESS的总处方需求年增12%。

此外，药理学创新和具有全新作用机制的治疗方法的引入推动了收入成长，这些疗法提高了疑难病例的疗效。产业正朝着下一代药物发展，其中钠氢交换器3 (NHE3) 抑制剂和鸟苷酸环化酶C促效剂的市场份额正在迅速增长。这种趋势在财务表现中显而易见。 Alderix公司在2025年10月发布的第三季财报中指出，由于处方医生对该药物的接受度提高，其创新药物IBSRELA的净销售额达到7,820万美元。此外，Ironwood Pharmaceuticals公司在2025年2月发布的报告中指出，LINZESS在美国的独立净销售额在2024年达到9.163亿美元，凸显了这些专科疗法的巨大商业性价值。

市场挑战

全球慢性特发性便秘治疗市场面临的一大障碍是患者对膳食补充剂和非处方泻药的过度依赖。这种根深蒂固的自我用药习惯严重阻碍了处方药的普及，因为患者通常会在寻求专业建议之前先选择价格低廉且易于取得的非处方产品。因此，慢性特发性便秘的正式诊断常常被延误或忽略，导致相当一部分潜在患者无法获得能够创造市场利益的、先进的高价值处方药治疗。

这种不愿介入的态度限制了专科药物的普及，即便严重的症状需要专科治疗。当患者认为非处方药就足够时，无论其长期疗效如何，药厂在取得市场份额方面都面临挑战。例如，美国胃肠病学会2024年的一项调查发现，95%的便秘患者表示排便时需要用力，这表明儘管尝试自我护理，症状负担仍然很重。这种症状严重程度与持续依赖非处方药之间的脱节抑制了处方药疗法的普及，直接阻碍了市场的成长。

市场趋势

製药公司正不断扩大适应症范围，将儿童族群纳入其中，拓宽了慢性特发性便秘治疗的潜在患者群。製造商正寻求监管部门批准，将已上市的鸟苷酸环化酶C促效剂的使用范围扩展至青少年和儿童，而这一人群以往只能使用渗透性泻药和仿单标示外核准。此举旨在满足儿童功能性肠道疾病领域的重要未满足需求，同时展现出对低龄患者的安全性。根据《製药技术》杂誌2025年11月报道，美国食品药物管理局（FDA）已核准Linzess用于治疗7岁及以上以便秘大肠激躁症儿童，有效拓展了该药物的市场覆盖范围，使其不再局限于传统的成人适应症。

同时，随着非专利药促动力药的上市，竞争格局正在重塑，成本障碍也随之降低。随着专利到期，生物等效替代药物已进入市场，扩大了先前因品牌药高昂自付费用而受限的患者的治疗机会。这些低成本替代药物的出现，使得医疗服务提供者能够更频繁地开立专科促动力药，从而推动了该类药物处方量的成长。例如，ANI製药公司宣布将于2025年1月在美国推出首个学名药Motegrity（普鲁卡必利），目标市场为年销售额估计为1.68亿美元的品牌药市场。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球慢性特发性便秘治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物类别（容积性泻药、润肤剂、刺激性泻药、渗透性泻药）
    • 给药途径（口服、注射）
    • 按分销管道（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美慢性特发性便秘治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲慢性特发性便秘治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区慢性特发性便秘治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东与非洲慢性特发性便秘治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章 南美洲慢性特发性便秘治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球慢性特发性便秘治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • GSK PLC
  • Astellas Pharma Inc
  • Synergy Pharmaceuticals Inc.
  • Bayer AG
  • Allergan PLC
  • Sanofi SA
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • Zydus Lifesciences Ltd
  • Boehringer Ingelheim GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18866

The Global Chronic Idiopathic Constipation Therapeutic Market is projected to expand from USD 11.53 Billion in 2025 to USD 16.46 Billion by 2031, reflecting a compound annual growth rate of 6.11%. This sector encompasses pharmaceutical agents and prescription treatments specifically developed for persistent constipation cases lacking a distinct physiological or systemic origin. Growth is primarily driven by the increasing prevalence of functional gastrointestinal disorders, an aging global population prone to reduced colonic motility, and rising healthcare investments in chronic disease management. Additionally, shifts toward sedentary lifestyles and dietary changes are enlarging the patient base needing medical attention. The International Foundation for Gastrointestinal Disorders noted in 2024 that constipation affects approximately 1 in every 6 to 7 individuals globally, highlighting the significant need for effective therapeutic solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.53 Billion
Market Size 2031USD 16.46 Billion
CAGR 2026-20316.11%
Fastest Growing SegmentParenteral
Largest MarketNorth America

Despite these positive indicators, the market confronts a major obstacle regarding widespread consumer dependence on over-the-counter laxatives and dietary supplements. A substantial number of individuals experiencing symptoms opt for self-medication with affordable, accessible alternatives rather than pursuing professional medical diagnoses, a behavior that postpones the shift to advanced prescription therapies. This tendency significantly constrains the addressable audience for specialized chronic idiopathic constipation therapeutics and hinders broader revenue growth within the sector.

Market Driver

The rising global incidence of chronic idiopathic constipation, fueled by sedentary lifestyles and dietary modifications, serves as a primary engine for market expansion. As urbanization accelerates and physical activity diminishes, the prevalence of functional bowel disorders has increased, resulting in a larger patient population requiring medical care. This dynamic has led to a noticeable shift of patients moving from over-the-counter remedies to prescription-grade treatments, creating consistent demand for established therapies. Recent industry metrics reflect this trend; according to Ironwood Pharmaceuticals' Third Quarter 2025 Results released in December 2025, total prescription demand for LINZESS rose by 12% compared to the prior year.

Revenue growth is further stimulated by pharmacological innovations and the introduction of therapies with novel mechanisms of action, which offer enhanced efficacy for difficult-to-treat cases. The sector is evolving toward next-generation agents, including sodium-hydrogen exchanger 3 (NHE3) inhibitors and guanylate cyclase-C agonists, which are quickly capturing market share. This adoption is evidenced by financial performance; Ardelyx reported in its October 2025 Third Quarter Financial Results that net product sales for the novel agent IBSRELA hit $78.2 million due to increased prescriber uptake. Additionally, the significant commercial value of these specialized treatments is highlighted by Ironwood Pharmaceuticals' February 2025 report, which noted that full-year 2024 U.S. net sales for LINZESS alone reached $916.3 million.

Market Challenge

A major hurdle inhibiting the Global Chronic Idiopathic Constipation Therapeutic Market is the extensive patient reliance on dietary supplements and over-the-counter laxatives. This deeply rooted habit of self-medication establishes a significant barrier to prescription therapy adoption, as individuals usually utilize affordable, readily available retail products before seeking professional advice. Consequently, formal diagnoses of Chronic Idiopathic Constipation are often delayed or overlooked, effectively preventing a substantial segment of the potential patient base from accessing advanced, higher-value prescription treatments that generate market revenue.

This hesitation to pursue medical intervention limits the reach of specialized therapeutics, even when severe symptoms warrant professional care. Pharmaceutical manufacturers face difficulties in gaining market share when patients view non-prescription alternatives as sufficient, regardless of their actual long-term effectiveness. For instance, the American College of Gastroenterology reported in a 2024 real-world survey that 95% of patients with constipation-related issues experienced straining during bowel movements, indicating a heavy symptom burden that remains despite self-care attempts. This gap between high symptom severity and persistent dependence on retail solutions curtails the uptake of prescription therapies, directly impeding the market's financial growth.

Market Trends

Pharmaceutical companies are increasingly expanding label indications to include pediatric populations, thereby widening the addressable patient base for chronic idiopathic constipation therapeutics. Manufacturers are securing regulatory approvals to extend the use of established guanylate cyclase-C agonists to adolescents and children, a group previously restricted to osmotic laxatives or off-label treatments. This strategic development targets a significant unmet need within pediatric functional bowel disorders while validating safety profiles for younger users. As reported by Pharmaceutical Technology in November 2025, the FDA approved Linzess for children aged seven and older with irritable bowel syndrome with constipation, effectively expanding the drug's market reach beyond its original adult indications.

Concurrently, the competitive landscape is being reshaped by the introduction of generic prokinetic agents, which are lowering cost barriers. The patent expiration for serotonin-4 receptor agonists has prompted the release of bioequivalent alternatives, making treatments more accessible to patients limited by the high out-of-pocket expenses associated with branded drugs. This availability of lower-cost options enables healthcare providers to prescribe specialized prokinetics more frequently, boosting volume growth in this segment. For example, ANI Pharmaceuticals announced in January 2025 the launch of the first U.S. generic version of Motegrity (prucalopride), targeting a branded market estimated at $168 million annually.

Key Market Players

  • GSK PLC
  • Astellas Pharma Inc
  • Synergy Pharmaceuticals Inc.
  • Bayer AG
  • Allergan PLC
  • Sanofi SA
  • Pfizer Inc
  • Takeda Pharmaceutical Co Ltd
  • Zydus Lifesciences Ltd
  • Boehringer Ingelheim GmbH

Report Scope

In this report, the Global Chronic Idiopathic Constipation Therapeutic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Idiopathic Constipation Therapeutic Market, By Drug Class

  • Bulk-Forming Agents
  • Emollients
  • Laxatives
  • Osmotic Agents

Chronic Idiopathic Constipation Therapeutic Market, By Route of Administration

  • Oral
  • Parenteral

Chronic Idiopathic Constipation Therapeutic Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Idiopathic Constipation Therapeutic Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Idiopathic Constipation Therapeutic Market.

Available Customizations:

Global Chronic Idiopathic Constipation Therapeutic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Bulk-Forming Agents, Emollients, Laxatives, Osmotic Agents)
    • 5.2.2. By Route of Administration (Oral, Parenteral)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Chronic Idiopathic Constipation Therapeutic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Chronic Idiopathic Constipation Therapeutic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Chronic Idiopathic Constipation Therapeutic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GSK PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Astellas Pharma Inc
  • 15.3. Synergy Pharmaceuticals Inc.
  • 15.4. Bayer AG
  • 15.5. Allergan PLC
  • 15.6. Sanofi SA
  • 15.7. Pfizer Inc
  • 15.8. Takeda Pharmaceutical Co Ltd
  • 15.9. Zydus Lifesciences Ltd
  • 15.10. Boehringer Ingelheim GmbH

16. Strategic Recommendations

17. About Us & Disclaimer